Body mass index and achievement of minimal disease activity in psoriatic arthritis across different classes of advanced therapy
Clicks: 3
ID: 317161
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.6
/100
3 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #111 of 206 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 206 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
OBJECTIVES: Obesity is a prevalent comorbidity in psoriatic arthritis (PsA). We aimed to evaluate the association between body mass index (BMI) and minimal disease activity (MDA) state in PsA and examine this across different drug classes. METHODS: In a longitudinal observational study using the Gladman Krembil PsA Program cohort, patients with available BMI measurement over follow-up were included. Univariable and multivariable (MV) generalized estimating equations and linear mixed models were used to assess associations between BMI and MDA (and its components) over time, adjusting for age, sex, anxiety/depression, fibromyalgia, smoking, treatment type, and radiographic damage. Subgroup analyses evaluated this association across six drug classes: TNFi, IL-17i, IL-12/23i, IL-23i, JAKi, and PDE4i. RESULTS: In 1291 patients (mean age 44.7 years, 56% male, mean BMI 28.8 kg/m2), higher BMI was independently associated with lower odds for MDA (MV, OR 0.97, 95% CI 0.94-0.99) along with female sex, older age, smoking, fibromyalgia, and radiographic damage. BMI was negatively associated with all MDA components except swollen joint count. Higher BMI at drug initiation was associated with reduced odds for MDA state in TNFi-treated patients excluding infliximab (MV, OR 0.93, 95% CI 0.90-0.96), while no significant effect was seen for IL-17i, IL-12/23i, IL-23i, or JAKi. Longitudinal BMI assessment similarly showed reduced MDA odds with TNFi (excluding infliximab). CONCLUSIONS: High BMI decreases the odds for MDA in PsA, mainly affecting subjective disease measures. This effect is most pronounced in patients treated with TNFi (except infliximab). This underscores the importance of weight management in optimizing treatment response.
| Reference Key |
openalex_W7164514374
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Pankti Mehta, Mu Yang, Fadi Kharouf, Virginia Carrizo Abarza, Shangyi Gao, Richard J Cook, Dafna D Gladman, Vinod Chandran, Denis Poddubnyy |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag303
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.